3-Methyladenine (3-MA)

For research use only.

Catalog No.S2767 Synonyms: NSC 66389

527 publications

3-Methyladenine (3-MA) Chemical Structure

CAS No. 5142-23-4

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.

Size Price Stock Quantity  
USD 70 In stock
USD 370 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's 3-Methyladenine (3-MA) has been cited by 527 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description 3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Targets
Vps34 [1]
(HeLa cells)		 PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
In vitro

The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. [1] 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. [2] Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. [3] Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5−/− MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2−/− cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. [4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K562 MmjHSpVv[3Srb36gRZN{[Xl? M2DEbVExdU1? NVTHPIo2OWh? NIfnOZpl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVEN|LVnJJIFv\CC2aHWg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTh4NECzO{c,OjF6NkSwN|c9N2F-
Jurkat Mo\NSpVv[3Srb36gRZN{[Xl? NUHjOHY6OTCvTR?= M1;SO|Fp MULk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUGM{NUmLIHHu[EB1cGViZn;ycYF1cW:wIH;mJIF2fG:yaHHnc5NwdWW| NHXVb409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUi2OFA{Pyd-MkG4OlQxOzd:L3G+
HeLa  MmDZR5l1d3SxeHnjbZR6KEG|c3H5 M4rXXVJuVQ>? NGfKS4szPGh? M4DWeolvcGmkaYTld{B1cGViY4n0c5RwgGmlaYT5JI9nKHOrbHnibY5qdiC2bzDI[WxiKGOnbHzzMi=> M37xNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEe1N|g2Lz5{MUi3OVM5PTxxYU6=
PC12/TetOn NYfL[454TnWwY4Tpc44hSXO|YYm= MVmwMlEwOW2P NXH4e4VROTiq MojqcIVi\HNidH:g{tEue3mwKGfULUBi[2O3bYXsZZRqd25uIITvfIlkcXS7LDDhcoQhd2yrZ3;t[ZIh\m:{bXH0bY9vyqB? NYDlOVA2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NFY3PTlpPkKxPVA3PjV7PD;hQi=>
RMPI8226  NYTDcplrTnWwY4Tpc44hSXO|YYm= M4TVNFVuVQ>? MlLzNYg> NH76UnF{fXCycnXzd4V{KHSqZTDs[ZZmdCCxZjDheZRweGijZ4mgeY5l\XJiboX0dolmdnRiZHXwcIV1cW:w MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTlzNU[yNEc,OjF7MUW2NlA9N2F-
MCF-7 M4HjTWZ2dmO2aX;uJGF{e2G7 NXXYbXhkOTCvTR?= MX60PIg> M3j6Z4Jtd2OtczDheZRweGijZ4mgbY5lfWOnZDDifUBjd3K2ZYrvcYlj NHe4N4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUmzNVk{Pyd-MkG5N|E6Ozd:L3G+
HBx  M1faZmFxd3C2b4Ppd{BCe3OjeR?= NETP[YcyOG2P NUix[nlRPDiq NEm0VVdFVVOR NXzFOGFGcW6lcnXhd4V{KGOnbHyg[IVifGh? MnHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyMkCwO|goRjJ{MEKwNFc5RC:jPh?=
Marc-145 NXr5TlZYTnWwY4Tpc44hSXO|YYm= NYXjcoZ2PW2P NFjWS5kyOi9{ND:zOog> NUPBUJZoemWmdXPld{B1cGViUGLSV3YhfGm2ZYLzJIFv\CC2aHWgdJJwfGWrbjDlfJBz\XO|aX;u MoPHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzMUm5NFAoRjJ{MUG5PVAxRC:jPh?=
U937 NETkWpFHfW6ldHnvckBCe3OjeR?= NE\WOIgzdU1? NH\NNW8yOmh? NVfsS3BW\GWlcnXhd4V{KHSqZTDheZRweGijZ4mgdoF1cW0EoB?= MlXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNUWxOVAoRjJ{MUW1NVUxRC:jPh?=
BGC-823 MlL6SpVv[3Srb36gRZN{[Xl? NIrSbGU2dU1? MnvNNog> MlrObY5pcWKrdIOgeIhmKHKjdHWgc4Yh[XW2b4DoZYdq[yClZXzsdy=> NYOxR2lkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNlIyPTJpPkKyN|IzOTV{PD;hQi=>
A549 MUXGeY5kfGmxbjDBd5NigQ>? M3;kb|AvOW2P MoC4NlRp NXzNOm1De3WycILld5NmeyCVVUGxNlc1NWmwZIXj[YQh[2WubDDk[YF1cA>? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR4Nkm2NEc,OjJ2Nk[5OlA9N2F-
pDCs M{jBe2Z2dmO2aX;uJGF{e2G7 MVSxNI1O NWLlRYROOC53aB?= NUfYOXY3yqC{ZXT1Z4V{KHSqZTDpcoR2[3Srb36gc4YhUU[QLd8xJIJ6KHO|Ul7BOFA> MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN7NkW5PUc,OjJ|OU[1PVk9N2F-
HeLa  MYnBdI9xfG:|aYOgRZN{[Xl? NGTCW|A2dU1? NV[ydlFpOjSq MULpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHPlcIwh\GWjdHi= NFfrV4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0OVEzQCd-MkK1OFUyOjh:L3G+
U251  NF7YfmhCeG:ydH;zbZMhSXO|YYm= M{i4fVVuVQ>? M1mxc|I1cA>? MoDibY5kemWjc3XzJHMyNWmwZIXj[YQh[2WubDDk[YF1cA>? NEnpTmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW3PVc5QCd-MkK1O|k4QDh:L3G+
MCF-7  M{jNXGFxd3C2b4Ppd{BCe3OjeR?= MWewMlFuVQ>? MXS2bC=> NX\tSIRL\W6qYX7j[ZMhe2m{dHnuc4wucW6mdXPl[EBieG:ydH;zbZM> NUDE[YFIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3OVE6QDlpPkKyO|UyQTh7PD;hQi=>
PC-3  M4XHfGFxd3C2b4Ppd{BCe3OjeR?= MkfQNo1O MV[ybC=> M{T6Uolv[3KnYYPld{BQWklvaX7keYNm\CClZXzsJIRm[XSq MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd2NUW4NEc,OjJ5NEW1PFA9N2F-
HCT116 NXjONXlUSXCxcITvd4l{KEG|c3H5 NYPwVJJ{PW2P NEPzO|MzPGh? M1HYZWROW09? MV7lcohidmOnczDhdIlo\W6rbj3pcoR2[2WmIHPlcIwh\GWjdHi= MkmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4Mk[1NlIoRjJ2NkK2OVIzRC:jPh?=
U2OS NULkN2JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPPNVBuVQ>? NFHTOpMzPGh? NGj5fVBqdnSnboPp[olmeyC2aHWg[5Jwf3SqIHnubIljcXSrb36gbY5lfWOnZDDifUBFd3h? M3XnTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkO5NFE{Lz5{NE[zPVAyOzxxYU6=
A2780cp MXvBdI9xfG:|aYOgRZN{[Xl? MmjXNk42dU1? MlvLNYg> MV7k[GgzVw>? MWrlcohidmOnczDjbZNxdGG2aX6tbY5lfWOnZDDj[YxtKGSnYYTo MnjFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MUe5OFYoRjJ2OEG3PVQ3RC:jPh?=
HepG2 Mn72SpVv[3Srb36gRZN{[Xl? M4TLVVVuVQ>? MUK0bC=> MVrpcoNz\WG|ZYOgZ4VtdHWuYYKgcIV3\Wy|IH;mJGhNyqB? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDdzM{W4O{c,OjR5MUO1PFc9N2F-
Microglia  NWTLb2N7SXCxcITvd4l{KEG|c3H5 MnLWOY1O NI\1cI4zPGh? MmC0[IVkemWjc3XzJIh6eG:6aXGtbY5lfWOnZDDj[YxtKGSnYYTo M33TUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEG4OlAyLz5{NEixPFYxOTxxYU6=
MDA-MB 231 MVHBdI9xfG:|aYOgRZN{[Xl? MUK1cW0> MV:wMlVp NXjRNnpsdW:mdXzheIV{KFSxY3;tbY7DtsLiaX7keYNm\CCjcH;weI9{cXN? MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|MEe4NUc,OjR6M{C3PFE9N2F-
PANC-1  MV3BdI9xfG:|aYOgRZN{[Xl? MVmxcW0> NULYXWFoPDiq NXnWfVI4TE2VTx?= Mn\h[Y5p[W6lZYOgZo9zfGW8b33pZk1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh2MkG1PEc,OjR6NEKxOVg9N2F-
MDA-MB-231 NEX6Z2JHfW6ldHnvckBCe3OjeR?= NWHmVlN3Om2P MWO0PIg> M1jYeJBzd22xdHXzJHRONWmwZIXj[YQh[2WubDDk[YF1cA>? M13LSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUewOlc3Lz5{NEm3NFY4PjxxYU6=
MDA-MB-231 MU\GeY5kfGmxbjDBd5NigQ>? MofTNo1O NWqzOoNXOjSq MV7pcohq[mm2czDheZRweGijZ4mgbY5lfWOnZDDifUBVVcLi NF;Mb|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm3NFY4Pid-MkS5O|A3PzZ:L3G+
MCF-7  MmX0SpVv[3Srb36gRZN{[Xl? MUmycW0> NIHCVZA1QGh? NFXYcIVxem:vb4Tld{BVVS2rbnT1Z4VlKGOnbHyg[IVifGh? NGXxbXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm3NFY4Pid-MkS5O|A3PzZ:L3G+
MCF-7  NHW1cmdHfW6ldHnvckBCe3OjeR?= M{nzd|JuVQ>? MW[yOIg> NV;LdoFWcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=> MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl5ME[3Okc,OjR7N{C2O|Y9N2F-
HepG2 MXXBdI9xfG:|aYOgRZN{[Xl? NWHEeoRTO22P MXi1bC=> MkTpdoVlfWOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IGHEdy=> NWLNSGlDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4N|Y2QTVpPkKyPFM3PTl3PD;hQi=>
HeLa M3XCO2Fxd3C2b4Ppd{BCe3OjeR?= M4LJPVExdU1? MlraNog> M1\k[oRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDjc{11emWjdH3lcpQhf2m2aDDQSWk> NIr0dJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CwNFE{PSd-MkOwNFAyOzV:L3G+
SK-HEP-1 NF\K[FRCeG:ydH;zbZMhSXO|YYm= MV[xNI1O M4fodFFp NHfEN|Nxem:2ZXP0d{Bi\2GrboP0JIF2fG:yaHHnfUBidmRiaX7keYNmeyCjcH;weI9{cXNiaX6gZpVn[Wyrbj30doVifGWmIHPlcIx{ Mn3CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6NUi2OFkoRjJ{OEW4OlQ6RC:jPh?=
MDA-MB231 NWfWN|R3TnWwY4Tpc44hSXO|YYm= MXy1cW0> MlPxNYg> MoO0bY5kemWjc3XzJJJme3[ncnH0do9tNW2nZHnheIVlKGOjc4Dhd4Uh[WO2aY\heIlwdiCjbnSgZ4VtdCCmZXH0bC=> NGnITHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C4PFg2OCd-MkOwPFg5PTB:L3G+
PaCa44 MnfzRZBweHSxc3nzJGF{e2G7 MlzqNk42dU1? NYricpBkOWh? M3vhd5Jm\HWlZYRCpIdmdmmyaX6tcYVlcWG2ZXSgZZBweHSxc3nz Mm\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzMkSxNVIoRjJ|MUK0NVEzRC:jPh?=
T-47D Ml7MSpVv[3Srb36gRZN{[Xl? M3LQXlExdU1? M4DkTlJp MX3pcohq[mm2czDheZRweGijZ4mgdJJw[2W|czDhcoQhcW6lcnXhd4V{KHKjcHHtfYNqdiCrbnT1Z4VlKGGyb4D0c5Nqew>? NEjv[WM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNFAzPid-MkOzNFAxOjZ:L3G+
GTL-16  MljzRZBweHSxc3nzJGF{e2G7 M1T1TVVuVQ>? M4LpNlI1cA>? MVHy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGG|IHPvcZBiemWmIITvJINmdGy|IITy[YF1\WRid3n0bEBOTVRiaX7obYJqfG:{cx?= MoT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MUO0PVAoRjJ|M{GzOFkxRC:jPh?=
U251MG  NY\qbWtuTnWwY4Tpc44hSXO|YYm= Ml7NN41O NUTz[2NkOWh? MXPzeZBxemW|c3XzJGxEOy2LSTDwdo91\WmwIHX4dJJme3Orb36= MmO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|M{i2NVgoRjJ|M{O4OlE5RC:jPh?=
T24 M1XKPWZ2dmO2aX;uJGF{e2G7 Mni1NVBuVQ>? MkLnNYg> NEjWNZJz\WS3Y3XzJJRp\SClbHXheoFo\SCxZjDMR|Mh[W[2ZYKgZoFq[2GuaX6geJJm[XSvZX70 MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN3NEC4NEc,OjN|NUSwPFA9N2F-
HUVECs NIfWcYNHfW6ldHnvckBCe3OjeR?= M33pWlNuVQ>? NYTRdoFDOjSq NH3LRoFjdG:la4OgeIhmKHC{b4TlZ5RqfmViZX\m[YN1KG:oIILld5ZmemG2cn;sJIJ6KGmwaHnibZRqdmdiYYX0c5Bp[We7 NGfveoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O1PFkzQCd-MkOzOVg6Ojh:L3G+
MCF-7  MVHGeY5kfGmxbjDBd5NigQ>? MnPNOY1O NIDpXlMzPGh? M3X0PIlvcGmkaYTzJJN1[XK4YYTpc44ucW6mdXPl[EBifXSxcHjh[5k> M1S0cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{m1Olc6Lz5{M{O5OVY4QTxxYU6=
Hela  M{T0bWZ2dmO2aX;uJGF{e2G7 MYe1cW0> MXSyOIg> MYDpcohq[mm2czDzeIFzfmG2aX;uMYlv\HWlZXSgZZV1d3CqYXf5 MlHvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|OUW2O|koRjJ|M{m1Olc6RC:jPh?=
OR6 M1vnPGZ2dmO2aX;uJGF{e2G7 NYLQfZBzOTCvTR?= MnfXO|Jp M4ftOJN2eHC{ZYPz[ZMhUEOYIILldIxq[2G2aX;uJIFv\CCob4LtZZRqd25ib3[gZZV1d3CqYXfvd49u\XN? NHvZZ|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O5OVg4PSd-MkOzPVU5PzV:L3G+
HT-29  MkPnSpVv[3Srb36gRZN{[Xl? NHTv[JoydU1? M1zmc|Q5Nzl4aB?= MXzpcohq[mm2czDBUXBMKGmwZIXj[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq M2[zb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUC4NlczLz5{M{WwPFI4OjxxYU6=
SH-SY5Y NYKyWXpES3m2b4TvfIlkcXS7IFHzd4F6 Mn24OY1O M4LOW|I1cA>? NILa[pVqdmO{ZXHz[ZMhWEOQIITvfIlkcXS7 M37ieVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUK1NlY2Lz5{M{WyOVI3PTxxYU6=
Saos-2  NVm5d5ZLSXCxcITvd4l{KEG|c3H5 MkKzNY1O MVO5Oog> Mn7FbY5kemWjc3XzJINmdGxiZHXheIghcW6mdXPl[EBjgSCSQ2i= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4M{G3NUc,OjN3NkOxO|E9N2F-
1321N1 MYTDfZRwfG:6aXPpeJkhSXO|YYm= NYTHWnFyPW2P NHfpdXMzPGh? NH7yVoFxem:2ZXP0d{Bk\WyuIHHnZYlve3RiUFPOMYlv\HWlZXSgeI95cWOrdIm= M2nPTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUK1NlY2Lz5{M{WyOVI3PTxxYU6=
A2780 M3[5[mFxd3C2b4Ppd{BCe3OjeR?= MYi1cW0> M2nBclI1cA>? NVfn[m06[2:wdnXyeJMhTlS\N{KwJJdqfGhiQ1TEVEBqdnSxIHHuJIFl\Gm2aY\lJIVn\mWldDD0c5diemS|IHvpcIxqdmdib4\hdolidiClYX7j[ZIh[2WubIO= NVrwWFFkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PVIzQDFpPkKzOVkzOjhzPD;hQi=>
OV2008 NIPFUm5CeG:ydH;zbZMhSXO|YYm= NV:4bIQzPW2P NXi5XXdOOjSq NVnYVmZk[2:wdnXyeJMhTlS\N{KwJJdqfGhiQ1TEVEBqdnSxIHHuJIFl\Gm2aY\lJIVn\mWldDD0c5diemS|IHvpcIxqdmdib4\hdolidiClYX7j[ZIh[2WubIO= M3HHbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUmyNlgyLz5{M{W5NlI5OTxxYU6=
PC12  NFrnSoFHfW6ldHnvckBCe3OjeR?= M2\nV|ExdU1? Ml30NlRp NEPPXmh4[XSnch?= NYfkd|FMyqCrbnjpZol1eyClaIntc5RzgXC|aX6tcIls\SCycn;0[YF{d22jbDDhZ5Rqfmm2eT6= NXTkfJNqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NFM6PzlpPkKzOlA{QTd7PD;hQi=>
SH-SY5Y NH;5OmtCeG:ydH;zbZMhSXO|YYm= NFz4cnM2dU1? NGjBT2oycA>? MXXhZo9tcXOqZYOgZ4Vt[XO2cn;sJI5mfXKxcILveIVkfGm4ZTDl[oZm[3R? NYPueZVGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVk{QTVpPkKzOlE6Ozl3PD;hQi=>
SH-SY5Y M1r5XWZ2dmO2aX;uJGF{e2G7 MojLNY1O NF3vcWczPGh? MVvpcohq[mm2czD0bIUh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF;DVC=> NYDxNm96RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OFMyPDhpPkKzO|Q{OTR6PD;hQi=>
HepG2 NEXubYhHfW6ldHnvckBCe3OjeR?= NXj6e2Z7OTCvTR?= MYSyOIg> NFz4cGVqdmirYnn0d{B{cVSLR1HSMUBidmRiSFLTV{1qdmS3Y3XkJIF2fG:yaHHnfS=> M2D4WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OEG3NFQxLz5{M{ixO|A1ODxxYU6=
HeLa NFe1WGRHfW6ldHnvckBCe3OjeR?= MYOxNI1O MkHSNog> MYDzeZBxemW|c3XzJGxEOyCLSTDlfJBz\XO|aYPvci=> M2S0dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OE[0O|M5Lz5{M{i2OFc{QDxxYU6=
HONE-1  MWfGeY5kfGmxbjDBd5NigQ>? NUDXbGtHPW2P MmPpNYg> NXTNT3JWemWycnXzd4V{KD[{LX3l[IlifGWmIGLPV{Bxem:mdXP0bY9v NUTZNlN5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4PVI{PThpPkKzPFkzOzV6PD;hQi=>
MCF7 M2\U[WZ2dmO2aX;uJGF{e2G7 MmXvOY1O MYqyOIg> NF\jTYNqdmO{ZXHz[ZMhS3WRIHnu[JVk\WRiY3XscEBl\WG2aB?= MkO3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NkK2NlkoRjJ|OU[yOlI6RC:jPh?=
HO8910 NVTmNYR{SXCxcITvd4l{KEG|c3H5 MXWxNI1O MlfSNVJp M1HLbYVvcGGwY3XzJGIyQS2rbnT1Z4VlKGGyb4D0c5Nq NXHLUZVjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PFM3OTBpPkKzPVg{PjFyPD;hQi=>
SMMC-7721 MX7BdI9xfG:|aYOgRZN{[Xl? MkDVOY1O Mn[xNlRp NYXlZ3dE[XS2ZX71ZZRmeyCWTl[t{tEheHKxdHXjeIlwdiCjZ3HpcpN1KHOncoXtJJN1[XK4YYTpc44udWWmaXH0[YQh[XCxcITvd4l{ M3\4SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2ME[2Olk{Lz5{NEC2OlY6OzxxYU6=
Hep3B MnnDRZBweHSxc3nzJGF{e2G7 MUO1cW0> M3:wWFI1cA>? NUjy[2V4[XS2ZX71ZZRmeyCWTl[t{tEheHKxdHXjeIlwdiCjZ3HpcpN1KHOncoXtJJN1[XK4YYTpc44udWWmaXH0[YQh[XCxcITvd4l{ MnHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNk[2PVMoRjJ2ME[2Olk{RC:jPh?=
H460 MX\GeY5kfGmxbjDBd5NigQ>? MmTWNVBuVQ>? M1fsclRp M3z2eolv[3KnYYPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF5M{KwPEc,OjRzN{OyNFg9N2F-
A549 Mn;wSpVv[3Srb36gRZN{[Xl? MVyxNI1O NILONWI1cA>? NYDZU|dycW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliaYLyZYRq[XSrb36= NX;a[WZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFI4OzVpPkK0NVQzPzN3PD;hQi=>
H1299  NEHncFJHfW6ldHnvckBCe3OjeR?= M3ToXVExdU1? Mly3OIg> NXWxWHNDcW6lcnXhd4V{KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGh? M3rkfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUezNlA5Lz5{NEG3N|IxQDxxYU6=
WiDr NXfPenZDTnWwY4Tpc44hSXO|YYm= NIXSWlYyOG2P MXOxbC=> NEPMb4tqdmirYnn0d{BRS0KOLXnu[JVk\WRiTFOzJGlKKGW6cILld5Nqd25? NUXCcWRVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxPVA1QDlpPkK0NVkxPDh7PD;hQi=>
LoVo  NFT2dW9CeG:ydH;zbZMhSXO|YYm= NYPmO5RnPW2P Moe4OFhp MnT5[Y5p[W6lZYOgSGNCNWmwZIXj[YQh[XCxcITvd4l{Ng>? Mn;iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{MEG4NVIoRjJ2MkCxPFEzRC:jPh?=
HepG2 E47 MnX3SpVv[3Srb36gRZN{[Xl? NFHsNoYzNjWvTR?= MVi0PIg> MWrpcoNz\WG|ZYOgeIhmKHSxeHnjbZR6KG:oIFHBMEBDW09uIHHu[EBES2x2 MlfMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{N{O3N|goRjJ2MkezO|M5RC:jPh?=
RKO NHLXd2pHfW6ldHnvckBCe3OjeR?= M4Wxc|JuVQ>? MlfINYg> NFj3PJNFVVOR NHu1Z3NmdmijbnPld{Bk\WyuIHTlZZRpKGK7IHflcIRidmGveXPpci=> NYnPbppLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVE4PzdpPkK0NlkyPzd5PD;hQi=>
Hep3B M2DWcGFxd3C2b4Ppd{BCe3OjeR?= M36zdFJuVQ>? M{\McVEzcA>? M{Pr[GROW09? MVfpcohq[mm2czDBXmQ5ODV3LXnu[JVk\WRiY3XscEBl\WG2aB?= NFLTXHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5O|MxOCd-MkSyPVc{ODB:L3G+
ACHN-5968 NELBbGZCeG:ydH;zbZMhSXO|YYm= NVrUWIJ7PW2P NUf2b|R5O2h? MXTlcohidmOnczDwZYNtcXSjeHXsMY1m\GmjdHXkJIFxd3C2b4Ppd:Kh NHjJWXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOwOVYxPCd-MkSzNFU3ODR:L3G+
Huh7 MnXuRZBweHSxc3nzJGF{e2G7 MVyycW0> MonCNVJp M{C5WWROW09? NF7qPW1qdmirYnn0d{BCYkR6MEW1MYlv\HWlZXSgZ4VtdCCmZXH0bC=> M2XMOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm3N|AxLz5{NEK5O|MxODxxYU6=
UOK257 MUjBdI9xfG:|aYOgRZN{[Xl? M2fYRlVuVQ>? NXXafXJJO2h? MlLH[Y5p[W6lZYOgdIFkdGm2YYjlcE1u\WSrYYTl[EBieG:ydH;zbZPDqA>? Mon0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|MEW2NFQoRjJ2M{C1OlA1RC:jPh?=
ECSCs  MWPBdI9xfG:|aYOgRZN{[Xl? NFHUcmMyOG2P MYO0bC=> Mn7o[IVkemWjc3XzJJJieGGveXPpck11emWjdHXkJIFxd3C2b4Ppdy=> M1O2eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{G5NVA6Lz5{NEOxPVExQTxxYU6=
MCF-7  MkTWSpVv[3Srb36gRZN{[Xl? MWKxNI1O MVGyOIg> NF;jcXZqdmirYnn0d{B1cGViYYX0c5Bp[We7IHnu[JVk\WRiYomgZ4hmdW:2aHXyZZB6KGS{dXfz MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDNzNUW3PEc,OjR|MUW1O|g9N2F-
SGC-7901  MWPBdI9xfG:|aYOgRZN{[Xl? M1\T[lJuVQ>? MoD3NYg> NXXqc3dTcW6lcnXhd4V{KEODLUSgbY5lfWOnZDDhdI9xfG:|aYO= Ml:2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|MkGzOFAoRjJ2M{KxN|QxRC:jPh?=
SMMC-7721 MV;BdI9xfG:|aYOgRZN{[Xl? M2rmVlJuVQ>? NWLzeGZTOWh? NYnmOXpxcW6lcnXhd4V{KEODLUSgbY5lfWOnZDDhdI9xfG:|aYO= NWriOmdiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNlE{PDBpPkK0N|IyOzRyPD;hQi=>
T24 NWP1bYdDSXCxcITvd4l{KEG|c3H5 NXPj[JRQPW2P Mn:zNU42cA>? MnK5dI91\W62aXH0[ZMh[2WuZXPvfIljNWmwZIXj[YQh[XCxcITvd4l{ NWL1XoVPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOFkyPzZpPkK0N|Q6OTd4PD;hQi=>
NTUB1 MWnBdI9xfG:|aYOgRZN{[Xl? MoLJOY1O NUTySXR7OS53aB?= NV;wdolpeG:2ZX70bYF1\XNiY3Xs[YNwgGmkLXnu[JVk\WRiYYDvdJRwe2m| M1zN[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{S5NVc3Lz5{NEO0PVE4PjxxYU6=
MG-63 NXrMUGhISXCxcITvd4l{KEG|c3H5 NVfEdoZxOTCvTR?= M3vLV|EzcA>? NUKxZY9t\W6qYX7j[ZMhTFBvaX7keYNm\CCjcH;weI9{cXN? NE\oSJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1PFMxOSd-MkSzOVg{ODF:L3G+
MG-63 M1[5W2Fxd3C2b4Ppd{BCe3OjeR?= NI[2cVAxNjVxMX3N MnLBN|Jp MnKy[Y5p[W6lZYOgd4FtcW6xbYnjbY4ucW6mdXPl[EBk\WyuIHHwc5B1d3Orcx?= MljWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NUizOFIoRjJ2M{W4N|QzRC:jPh?=
MG-63 NEjIS5ZHfW6ldHnvckBCe3OjeR?= NV\jOlBHOC53L{HtUS=> NIjDZ2M1QGh? NGPwZllqdmS3Y3XzJJNidGmwb335Z4lvNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? NYXhepZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVg{PDJpPkK0N|U5OzR{PD;hQi=>
U2OS  MlfuSpVv[3Srb36gRZN{[Xl? MnrnNE42NzGvTR?= M1XxPFQ5cA>? M{Xleolv\HWlZYOgd4FtcW6xbYnjbY4ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ M{nKOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{W4N|QzLz5{NEO1PFM1OjxxYU6=
HGC-27 MnHNSpVv[3Srb36gRZN{[Xl? NF7kUZUyOG2P MW[xbC=> M{fz[4lvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBtd3O|IHL5JHJCTDByMTDvdkBOUy1{MkC2 NFq5dlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESxOlM1QSd-MkS0NVY{PDl:L3G+
HCT116  M4fEemFxd3C2b4Ppd{BCe3OjeR?= MmrWOY1O NX;kd2pDOjSq NHiyZ|hmdmijbnPld{B1cGViYYDvdJRwe2m|IHnu[JVk\WRiYomgZZBq\2WwaX6= M{O3TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkK2OVIzLz5{NE[yOlUzOjxxYU6=
A549 NHTZN3FCeG:ydH;zbZMhSXO|YYm= MUKxNI1O M1vNO|Q5cA>? NHrPTnBi[2OnbHXyZZRmeyC2aHWgdoVlfWO2aX;uJI9nKGOnbHygeoli[mmuaYT5JIlv\HWlZXSgZpkhWFS[ NXTj[IM4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NlY4OjJpPkK0OlI3PzJ{PD;hQi=>
Saos-2 MUXBdI9xfG:|aYOgRZN{[Xl? M1KyS|ExdU1? NWDoTm1GOjSq NUHTenRDcW62ZX7zbYZq\XNidHjlJIdzd3e2aDDpcohq[mm2aX;uJI9nKHSqZTDVNm9UKGOnbHzzJIlv\HWlZXSgZpkhTG:6 NFHHeoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zPVAyOyd-MkS2N|kxOTN:L3G+
U2OS MYTBdI9xfG:|aYOgRZN{[Xl? M1fPO|ExdU1? M2PxSlI1cA>? M4jsWYlvfGWwc3nmbYV{KHSqZTDndo94fGhiaX7obYJqfGmxbjDv[kB1cGViVULPV{Bk\WyuczDpcoR2[2WmIHL5JGRwgA>? M4fSUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkO5NFE{Lz5{NE[zPVAyOzxxYU6=
HepG2 NHHvfYJHfW6ldHnvckBCe3OjeR?= MVm1cW0> Mnv3OIg> NHjSSYFqdmO{ZXHz[ZMhUExicnXs[YF{\Q>? M4nUTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{GzOVg4Lz5{NEexN|U5PzxxYU6=
A549 MYDBdI9xfG:|aYOgRZN{[Xl? NGfLe402dU1? MV[0PIg> MkjO[IVkemWjc3XzJJRp\SCyZYLj[Y51[WenIH;mJINmdGxiZHXheIgh[W6mIHX4dJJme3Orb36gcIV3\Wy|IH;mJINie3Cjc3WtN{whSmWlbHnuMVEh[W6mIFzDN{1KUQ>? NGPLcVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEewOlMxOyd-MkS3NFY{ODN:L3G+
A2780cp M4HWbmFxd3C2b4Ppd{BCe3OjeR?= MV2yMlVuVQ>? NUP6WmltOWh? NYr5cmJp\GSKMl:= M4TVNoVvcGGwY3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhzN{m0Okc,OjR6MUe5OFY9N2F-
Microglia  NVXxUIJESXCxcITvd4l{KEG|c3H5 MW[1cW0> MkjBNlRp M3;aN4Rm[3KnYYPld{BpgXCxeHnhMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NXj5[45FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVg3ODFpPkK0PFE5PjBzPD;hQi=>
HT-29  MkH6RZBweHSxc3nzJGF{e2G7 NIfDeXYydU1? M3jveFQ5cA>? NUn1fXFqTE2VTx?= MoKx[Y5p[W6lZYOgZo9zfGW8b33pZk1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M> NWHRfldDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OFIyPThpPkK0PFQzOTV6PD;hQi=>
MDR NYTqPZFLSXCxcITvd4l{KEG|c3H5 MofkNVBuVQ>? NXXhN2RGPmh? NI\UWY9{fHKnbnf0bIVveyC2aHWgdI94\XJib3[gZY51cWOjbnPldkBlenWpcx?= NFi2coc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCxPVcxOSd-MkWwNVk4ODF:L3G+
H157 M{D6VmZ2dmO2aX;uJGF{e2G7 NUfyNHh[PW2P NEPnSGszcA>? NX7UOXBOe3WycILld5NmeyCVUFOgbY5lfWOnZDDhZ4N2dXWuYYTpc44hd2ZiTFOzMWlK MnOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OEW2NlgoRjJ3Mki1OlI5RC:jPh?=
A549  MX7GeY5kfGmxbjDBd5NigQ>? NHq0bHg2dU1? NVzMWXRPOmh? NXnuVGFDe3WycILld5NmeyCVUFOgbY5lfWOnZDDhZ4N2dXWuYYTpc44hd2ZiTFOzMWlK NYnWO4N{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPFU3OjhpPkK1Nlg2PjJ6PD;hQi=>
A2780cp  MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrJNY1O NEjrNW4ycA>? MUHpcoNz\WG|ZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> M124[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{KyOlk1Lz5{NUOyNlY6PDxxYU6=
NBL-W-S  NWLoVoo4SXCxcITvd4l{KEG|c3H5 NV7mUHdROW2P MlX6Oog> NEHEZZdqdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBISU6WLU[x NFX5cpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOyN|IzOid-MkWzNlMzOjJ:L3G+
NBL-W-S  M37GTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LkNFFuVQ>? NEL5fG03cA>? NICyb3FmdmijbnPld{BISU6WLU[xJJRwgGmlaYT5 MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN{M{KyNkc,OjV|MkOyNlI9N2F-
A549  Mlq0RZBweHSxc3nzJGF{e2G7 Mn7SOY1O NUfiU5hUOmh? NVPneVg4TE2VTx?= NY\aUoQxcW6qaXLpeJMhSkSPQz3pcoR2[2WmIHHwc5B1d3SrYzDj[YxtKGSnYYTo MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdzNkW2NUc,OjV5MU[1OlE9N2F-
95D M3K1WmFxd3C2b4Ppd{BCe3OjeR?= NGrtTGc2dU1? NVezPYQxOmh? MnLRSG1UVw>? M{jGcolvcGmkaYTzJGJFVUNvaX7keYNm\CCjcH;weI91cWNiY3XscEBl\WG2aB?= Ml\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MU[1OlEoRjJ3N{G2OVYyRC:jPh?=
A549  NGHMdopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrYd3M{dU1? M{eyWlJp MknuSG1UVw>? M1vsbJJm\HWlZYOg[5Jwf3SqIHnubIljcXSxcomg[YZn\WO2IH;mJGJFVUN? MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdzNkW2NUc,OjV5MU[1OlE9N2F-
95D NEPySFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nmSVNuVQ>? NIG4[FEzcA>? MV\EUXNQ M4jvdZJm\HWlZYOg[5Jwf3SqIHnubIljcXSxcomg[YZn\WO2IH;mJGJFVUN? M{HQOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{G2OVYyLz5{NUexOlU3OTxxYU6=
Nara-H NWG3WXY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3zOY1O MWe0PIg> MWHlcohidmOnczD0[Y1{cXKxbHnteZNu\WSrYYTl[EB{fXCycnXzd4lwdiCxZjDOZZJiNUhiY3XscEBxem:uaX\ldoF1cW:w MmLKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEWwN|MoRjJzOEC1NFM{RC:jPh?=
HUVECs MmfZSpVv[3Srb36gRZN{[Xl? NETP[nAyOG2P NEX4N3cxNjWq MnTZ[IVkemWjc3XzJJRp\SCDR1WtRnNCcW6mdXPl[EBifXSxcHjh[5khdGW4ZR?= NIrOc3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS2PFU6Oid-MkG0Olg2QTJ:L3G+
HepG2 NVu1cHpXSXCxcITvd4l{KEG|c3H5 NVvGZ5hTOm2P NILve|IycA>? MUTlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDj[YxtKGSnYYTo MmLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NUO2PVEoRjJzNEWzOlkyRC:jPh?=
U-2 OS MWLxTHRUKGG|c3H5 NFu0fGdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVT2yJG9UKGOnbHzz MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
A673 NVna[HN2eUiWUzDhd5NigQ>? M{Tqe5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| NInVcZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
DAOY MlTBdWhVWyCjc4PhfS=> MWrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>? NUWzeWJmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2 MmnWdWhVWyCjc4PhfS=> Mn;EdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?= MnXtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 M{PjeJFJXFNiYYPzZZk> MlHvdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy| MoLHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
RD MX7xTHRUKGG|c3H5 M1;UO5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? NH7yb5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH Mn3pdWhVWyCjc4PhfS=> NHPDTHdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=> NYT5TZJLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 MWrxTHRUKGG|c3H5 MXjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN? MkHmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R) NEDWd3FyUFSVIHHzd4F6 NVXDcHRmeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz M13STVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643 MVfxTHRUKGG|c3H5 M1LBW5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO= MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 NHL6e4NyUFSVIHHzd4F6 MkPqdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= NEn4dWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 NH7pVG9yUFSVIHHzd4F6 MUHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>? MlnvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh30 M4[zcZFJXFNiYYPzZZk> NXzQVFFGeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoN|Ah[2WubIO= Mm\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 M4WwN5FJXFNiYYPzZZk> NIPwfHZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> NX\0RlNHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC NIrufJdyUFSVIHHzd4F6 NVPXV4UzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> NW\KV5BKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 NUnzfXloeUiWUzDhd5NigQ>? MVnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?= NX[4cmtzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 NISySndyUFSVIHHzd4F6 NVzYUVJseUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz MlfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh18 M3nGVZFJXFNiYYPzZZk> MVHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>? MonzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
α-SMA / TGF-β / LC-3BI / LC-3B II / Beclin-1 / NF-κB p65; 

PubMed: 29296191     


Western blotting analysed expression of α-SMA, TGF-β, LC-3B, Beclin-1, NF-κB and NF-κBp65 in hepatic stellate cells.

caspase-3 / caspase-9 / PARP; 

PubMed: 25891159     


EC9706 cell lysates were prepared and subjected to immunoblotting with antibodies against caspase-3, caspase-9 and PARP. The expression ratios in each experiment were determined densitometrically. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; PI, propidum iodide; PARP, poly(ADP ribose) polymerase.

VEGF; 

PubMed: 25891159     


Effects of autophagy inhibition on the protein expression levels of VEGF. Western blot analysis demonstrated that VEGF protein expression levels were decreased when the EC9706 human esophageal squamous cell carcinoma cells were treated with 3-MA. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; VEGF, vascular endothelial growth factor.

APP / BACE1 / ADAM17 / Presenilin 1 / Presenilin 2 / Nicastrin / APH-1 / Pen-2 / LC3-1 / LC3-2; 

PubMed: 26316755     


Presenilin 1, Nicastrin, and Pen-2 were increased with the 3-MA treatment (*P<0.001) while the other component of the γ-secretase complex (APH-1 and Presenilin 2) has no difference. 3-MA, 3-methyladenine; Con, control; APP, amyloid protein precursor.

29296191 25891159 26316755
Immunofluorescence
LC3 / Hif-α / COX2; 

PubMed: 29039446     


Chemical interventions of autophagy and ischemic-hypoxic injury, assessed using immunochemical double labeling. Compared with the control group, expression levels of HIF-α and COX2 were altered by chemical intervention. (A) Chemical intervention altered the expression of HIF-α and autophagosmes. Following autophagy antagonist (3-MA) intervention, expression of HIF-α was enhanced, compared with that in the OGD group, and was decreased by the autophagy agonist, rapamycin. In the MHY treatment group, expression of HIF-α was similar to that in the 3-MA group. (B) Chemical intervention showed changes in the expression of COX2 and autophagosomes. Changes in the expression of COX2 were similar to changes in HIF-α. Scale bar, 30 µm. OGD, oxygen-glucose deprivation; HIF-α, hypoxia-inducible factor-α; COX2, cyclooxygenase 2; 3-MA, 3-methyladenine; RP, rapamycin; MHY, MHY1485.

29039446
Growth inhibition assay
Cell viability; 

PubMed: 26934124     


KYSE 180 cells were co-treated with EDHB (40 μg/ml) and various concentrations of 3-MA for 24 h (left) or 48 h (right), and cell viability was determined by WST-8 assays.

26934124
In vivo 3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. [5]

Protocol

Kinase Assay:[4]
- Collapse

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
Cell Research:[2]
- Collapse
  • Cell lines: HeLa cell line
  • Concentrations: 1-10 mM
  • Incubation Time: 24, 48 or 72 hours
  • Method: Cell (such as HeLa cell) viability is determined by a trypan blue exclusion assay. Briefly, after treated with 3-Methyladenine, both adherent and floating cells are collected and suspended in phosphate buffered saline (PBS, pH 7.4) at a final density of 1-2 × 106/mL. An equal volume of 0.4% trypan blue solution (w/v, in PBS) is added to the cell suspension and mixed thoroughly. After incubation at room temperature for 3 min, cell counting is performed using a hemacytometer.
    (Only for Reference)
Animal Research:[5]
- Collapse
  • Animal Models: Adult male Sprague–Dawley rats weighing 300-350 g
  • Dosages: 400 nM
  • Administration: Intracerebral ventricular
    (Only for Reference)

Solubility (25°C)

In vitro Water 10 mg/mL warmed (67.04 mM)
Ethanol 4 mg/mL (26.81 mM)
DMSO 3 mg/mL warmed (20.11 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 149.15
Formula

C6H7N5
CAS No. 5142-23-4
Storage powder
in solvent
Synonyms NSC 66389
Smiles CN1C=NC(=N)C2=C1N=CN2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution

  • Answer:

    As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

selleck catalog

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

  • Taselisib (GDC 0032) New

    Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with Ki of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147) New

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317 New

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • LY294002

    LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.

  • Idelalisib (CAL-101, GS-1101)

    Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.

  • Wortmannin

    Wortmannin (KY 12420) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.

  • Dactolisib (BEZ235)

    Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.

  • Buparlisib (BKM120)

    Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.

  • Pictilisib (GDC-0941)

    Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.

  • Alpelisib (BYL719)

    Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Tags: buy 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) supplier | purchase 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) cost | 3-Methyladenine (3-MA) manufacturer | order 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID